Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis: A Cohort Study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background: Low-dose glucocorticoids are frequently used for the management of rheumatoid arthritis (RA) and other chronic conditions, but the safety of long-term use remains uncertain. Objective: To quantify the risk for hospitalized infection with long-term use of low-dose glucocorticoids in patients with RA receiving stable disease-modifying antirheumatic drug (DMARD) therapy. Design: Retrospective cohort study. Setting: Medicare claims data and Optum's deidentified Clinformatics Data Mart database from 2006 to 2015. Patients: Adults with RA receiving a stable DMARD regimen for more than 6 months. Measurements: Associations between glucocorticoid dose (none, ≤5 mg/d, >5 to 10 mg/d, and >10 mg/d) and hospitalized infection were evaluated using inverse probability–weighted analyses, with 1-year cumulative incidence predicted from weighted models. Results: 247 297 observations were identified among 172 041 patients in Medicare and 58 279 observations among 44 118 patients in Optum. After 6 months of stable DMARD use, 47.1% of Medicare patients and 39.5% of Optum patients were receiving glucocorticoids. The 1-year cumulative incidence of hospitalized infection in Medicare patients not receiving glucocorticoids was 8.6% versus 11.0% (95% CI, 10.6% to 11.5%) for glucocorticoid dose of 5 mg or less per day, 14.4% (CI, 13.8% to 15.1%) for greater than 5 to 10 mg/d, and 17.7% (CI, 16.5% to 19.1%) for greater than 10 mg/d (all P < 0.001 vs. no glucocorticoids). The 1-year cumulative incidence of hospitalized infection in Optum patients not receiving glucocorticoids was 4.0% versus 5.2% (CI, 4.7% to 5.8%) for glucocorticoid dose of 5 mg or less per day, 8.1% (CI, 7.0% to 9.3%) for greater than 5 to 10 mg/d, and 10.6% (CI, 8.5% to 13.2%) for greater than 10 mg/d (all P < 0.001 vs. no glucocorticoids). Limitation: Potential for residual confounding and misclassification of glucocorticoid dose. Conclusion: In patients with RA receiving stable DMARD therapy, glucocorticoids were associated with a dose-dependent increase in the risk for serious infection, with small but significant risks even at doses of 5 mg or less per day. Clinicians should balance the benefits of low-dose glucocorticoids with this potential risk. Primary Funding Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additional studies have corroborated these findings, linking even low dose glucocorticoid use (prednisone 2.5-7.5 mg/day) to increased risks of cardiovascular disease (9), severe infections (10), hypertension (11), diabetes (12), osteoporosis and fractures (13, 14), and increased overall mortality with concurrent type 2 diabetes mellitus (15).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796 · cited 1×
“Propensity scores were used to create stabilized inverse probability treatment weights (26–28) truncated at the first and 99th percentiles (29).”
Method2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Self-citationSmolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057 · cited 5×
“They are widely accepted for short-term use as bridging therapy in patients starting or changing treatment with DMARDs (4, 5), with the goal of their eventual withdrawal.”
BackgroundInfluentialA tutorial on propensity score estimation for multiple treatments using generalized boosted models
McCaffrey, D. F., Griffin, B. A., Almirall, D., Slaughter, M. E., Ramchand, R., & Burgette, L. F. (2013) · Statistics in Medicine · doi:10.1002/sim.5753 · Cited by 1,450
A combined comorbidity score predicted mortality in elderly patients better than existing scores
Gagne, J. J., Glynn, R. J., Avorn, J., Levin, R., & Schneeweiss, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.10.004 · Cited by 995 · cited 2×
“Covariates measured during the baseline period included age, sex, race, geographic region, calendar year, comorbidities, an adaption of the Charlson Comorbidity Index (23), health care use (outpatient visits, rheumatologist outpatient visits, emergency department visits, and hospitalizations), previous hospitalized in…”
BackgroundSchneeweiss, S. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1200 · Cited by 727 · cited 1×
“To assess the effect of an unmeasured confounder (disease activity) on results, we did a residual bias assessment (30) using C-reactive protein (CRP) level in a subset of patients in Optum.”
MethodSingh, J. A., Cameron, C., Noorbaloochi, S., Cullis, T., Tucker, M., Christensen, R., Ghogomu, E. T., Coyle, D., Clifford, T., Tugwell, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61704-9 · Cited by 623
Wolfe, F., Caplan, L., & Michaud, K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21568 · Cited by 480
Curtis, J. R., Patkar, N., Xie, A., Martin, C., Allison, J. J., Saag, M., Shatin, D., & Saag, K. G. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22504 · Cited by 398 · cited 1×
“The primary outcome definition was the presence of an ICD-9 diagnosis of infection (Supplement Table 1) in any position of the discharge diagnoses from an acute care hospitalization (positive predictive value >80%) (13, 22).”
BackgroundSelf-citationGrijalva, C. G., Chen, L., Delzell, E., Baddley, J. W., Beukelman, T., Winthrop, K. L., Griffin, M. R., Herrinton, L. J., Liu, L., Ouellet-Hellstrom, R., et al. (2011) · JAMA · doi:10.1001/jama.2011.1692 · Cited by 350
Self-citation
Cited by
Items 101–200 of 207
Adas, M. A., Bechman, K., Russell, M., Allen, V., PATEL, S. N., Gibson, M., Karafotias, I., Biddle, K., Zuckerman, B. P., Song, K., et al. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf312 · Cited by 5
“Long-term use of high doses ( > 10 mg/day) has been associated with more than double the risk of SI [17, 20, 21].”
Mori, Y., Tarasawa, K., Tanaka, H., Kanabuchi, R., Hatakeyama, H., Mori, N., Fushimi, K., Aizawa, T., & Fujimori, K. (2025) · Modern Rheumatology · doi:10.1093/mr/roaf067 · Cited by 4
Navigating Comorbidities in Chronic Inflammatory Rheumatic Diseases: Insight and Strategies
Hmamouchi, I., Jaoude, S. B., & Ziadé, N. (2024) · touchREVIEWS in RMD · doi:10.17925/rmd.2024.3.1.4 · Cited by 4
Mezochow, A. K., Schaubel, D. E., Peyster, E. G., Lewis, J. D., Goldberg, D. S., & Bittermann, T. (2024) · Transplant Infectious Disease · doi:10.1111/tid.14317 · Cited by 4
“There was a significant difference between types of early and late OIs, which may reflect the different risk factors for these groups.”
InfluentialPalmowski, A., Roberts, E. T., Li, J., Kersey, E., Stovall, R., Buttgereit, F., Yazdany, J., & Schmajuk, G. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152535 · Cited by 4
Raza, S. H. A., Huang, Z., Pang, Y., Zhong, R., Li, X., Pant, S. D., Luo, L. G., & Lei, H. (2024) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2024.105447 · Cited by 4
Pulmonary Immunocompromise in Chronic and High-dose Steroid Therapy
Kang, M., & Cavallazzi, R. (2024) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2024.10.012 · Cited by 5
Li, Q., Wang, D., & Fan, H. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s516013 · Cited by 3
“All included predictors were highly significant (p < 0.001), reinforcing their importance in predicting new infections.”
InfluentialOku, K., Yamada, H., Ikenoue, T., Akizuki, M., Hagiyama, H., Ideguchi, H., Ihata, A., Kakutani, T., Kawahata, K., Matsui, T., et al. (2025) · Modern Rheumatology · doi:10.1093/mr/roaf061 · Cited by 3
The impact of glucocorticoids on the efficacy of JAK inhibitors or non-TNF-targeted biologics in RA
Salvato, M., Salvatori, B., Frizzera, F., Arru, F., Khalid, K., Luozzo, L. D., Zen, M., Doria, A., & Giollo, A. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf612 · Cited by 4
Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Where Are We?
Gourbeyre-Masson, K., Landon‐Cardinal, O., Benvéniste, O., & Allenbach, Y. (2024) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-023-00214-y · Cited by 3
“In addition, CS are associated with many other side effects including hypertension, diabetes, weight gain, osteoporosis, and muscle weakness (CS-induced myopathy) [13–15].”
Lan, Y. W., Hu, D., Huang, S., Ma, Q., Chen, L., Xu, M., & He, Q. (2024) · International Journal of COPD · doi:10.2147/copd.s466588 · Cited by 3
“17,18,22,23 In addition, as shown in Table 3, the reported incidence of eye infections caused by Triamcinolone Acetonide was significantly higher than other ICS or INCs.”
BackgroundSelf-citationBradbury, T., Tanna, G. L. D., Scaria, A., Martin, A., Wen, F.-Q., Zhong, N.-S., Zheng, J.-P., Barnes, P. J., Celli, B. R., Berend, N., et al. (2022) · International Journal of COPD · doi:10.2147/copd.s339889 · Cited by 3
“A recent cohort study reported that rheumatoid arthritis participants prescribed low-dose systemic glucocorticosteroids were significantly more likely to be admitted to hospital for infection.(29,30) With the existing TASCS data, it was not possible to determine if this proposed mechanism is responsible, as no sputum…”
BackgroundMedications, Therapeutic Modalities, and Regimens Used in the Management of Rheumatic Diseases
Moutsopoulos, H. Μ., & Zampeli, E. (2020) · Springer eBooks · doi:10.1007/978-3-030-56670-8_14 · Cited by 4
Immunomodulatory effect of pachymaran on cyclosporine A (CsA)-induced lung injury in mice
Kaiqin, C., Wei, K., Chun, Y., Tianhao, Z., Zhang, B., Xiao, R., & Fangguo, L. (2022) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2022.06.011 · Cited by 3
Jo, H.-G., Seo, J., Baek, E., Hwang, J. H., & Lee, D. (2023) · Medicine · doi:10.1097/md.0000000000033903 · Cited by 3
“[17] In contrast, symptomatic drugs, such as DMARDs and glucocorticoids, have also been reported to have subsafety concerns, such as increasing the risk of infection even at low doses.[18] Moreover, patients who are unresponsive despite receiving active therapies, such as multiple DMARD combination therapy, are also a…”
BackgroundGoto, Y., Nagafuchi, H., Kaga, Y., & Kawahata, K. (2023) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14851 · Cited by 3
Xie, W., Huang, H., Geng, Y., Fan, Y., & Zhang, Z. (2024) · Rheumatology International · doi:10.1007/s00296-024-05713-2 · Cited by 3
“First, exposure to GC has been associated with frequent toxic effects in multiple organ systems in a dose-and time-dependent or independent manner [5, 6].”
Adverse effects of oral glucocorticoid therapy - a brief review of literature
Gruszka, M., Polańska, P., Kubicka, M., Zakrocka, M., & Fick, J. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.78.57512 · Cited by 3
Orange, D. E., & Mehta, B. Y. (2020) · Annals of Internal Medicine · doi:10.7326/m20-6010 · Cited by 3
“In their article, George and colleagues (7) elucidate the risk for infection from this strategy by reporting an elegant analysis of RA patient data from 2 databases: Medicare claims data, representing federally insured older patients, and Optum's Clinformatics Data Mart, representing commercially insured younger patie…”
Putra, O. N., Anggraini, M. A., & Hardiyono, H. (2022) · Journal of Islamic Pharmacy · doi:10.18860/jip.v6i2.12884 · Cited by 2
Ota, R., Hirata, A., Hata, T., Nishihara, M., Neo, M., & Katsumata, T. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2946 · Cited by 2
Kashiwagi, H., Miura, I., Terasawa, N., Iwayama, K.-I., Furukawa, Y., & Kanenishi, M. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03897-8 · Cited by 2
“Although the European League Against Rheumatism (EULAR) reported that the risk of harm in long-term treatment below 5 mg/ day was low in most patients [8], even low doses of CS can lead to fracture and infection when used concomitantly with immunosuppressants [9, 10].”
Komiya, Y., Sugihara, T., Ishizaki, T., Kimura, N., Kamiya, M., Hirano, F., Matsumoto, T., Sasaki, H., Hosoya, T., Tohma, S., et al. (2025) · Clinical Rheumatology · doi:10.1007/s10067-025-07599-2 · Cited by 2
“The use of GCs for older RA patients in the long term was associated with multi-comorbidities such as serious infectious events [20–23], sarcopenia [24 , 25], cardiovascular events [26], and fractures [27].”
van Sleen, Y., van der Geest, K. S. M., Reitsema, R. D., Esen, İ., Terpstra, J. H., Raveling‐Eelsing, E., van der Heiden, M., Lieber, T., Buisman, A., van Baarle, D., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002479 · Cited by 2
Hsu, Y. A., Yang, T., Huang, S., & Lan, C.-C. E. (2023) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12731 · Cited by 2
“39,40 In our study, the patients who expired due to severe sepsis or massive gastro-intestinal bleeding within 12 months of follow-up belonged to the DPP4i-C group.”
Zhou, M., Lu, C., & Yuan, F. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s432366 · Cited by 2
“26,27 As a result, rheumatologists must weigh the benefits of low-dose glucocorticoids against the possibility of side effects.”
BackgroundXu, X.-X., Shao, H., Wang, Q.-X., & Wang, Z.-Y. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073263839231129163200 · Cited by 2
Carvajal-Gutiérrez, W., Cisneros-Cisneros, M. A., Calixto, O.-J., Meneses-Toro, M. A., Rueda, A., Vega-Báez, M. A., Álvarez-Vargas, D. A., Uscategui-Ruiz, A. C., Romero‐Sánchez, C., & Bello-Gualtero, J. M. (2024) · Current Rheumatology Reviews · doi:10.2174/0115733971290285240207080745 · Cited by 2
Vasavada, K. D., Lin, C. C., Jazrawi, L. M., & Samuels, J. (2024) · The Physician and Sportsmedicine · doi:10.1080/00913847.2024.2324363 · Cited by 2
“…in a cohort study of Medicare and MarketScan Data, George et al. reported an elevated, but similar risk of hospitalized infection and prosthetic joint infection across commonly used biologics, and a dose-dependent increase in risk with glucocorticoids starting as low as 5–10 grams per day [21,22].”
Torii, S., Torii‐Goto, A., Tanizawa, T., Sakakibara, T., Oguri, R., Nagase, H., Nakao, Y., Hirashita, T., Tanaka, K., Takimoto, N., et al. (2024) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-024-00391-5 · Cited by 2
“…serious infections was 30% after 3 months, 46% after 6 months and 100% after 3 years from initiation, compared with that without the use of steroids; and the risk associated with the use of 5 mg/day of PSL for 3 years was determined to be equivalent to the use of 30 mg/day for a month [11, 24, 25].”
Emery, P., Fleischmann, R., Wong, R. L., Lozenski, K. L., Tanaka, Y., Bykerk, V. P., Bingham, C. O., Huizinga, T. W. J., Citera, G., Perera, V., et al. (2025) · The Journal of Rheumatology · doi:10.3899/jrheum.2024-0498 · Cited by 2
Yao, C., Zhang, C., Song, M.-G., Xia, C., Chang, T., Ma, X., Liu, W., Liu, Z.-X., Liu, J.-M., Tang, X., et al. (2025) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-025-4212-3 · Cited by 2
“…than 12 months (n=545), the results continued to show that age 60 (P=0.002, HR=1.953, 95% CI: 1.272–2.998), absence of NSAID use (P=0.004, HR=3.128, 95% CI: 1.434–6.823), and an IM regimen (P=0.031, HR=1.910, 95%CI: 1.060–3.442) were the primary predictors of early GC discontinuation (Appendix 7).”
InfluentialAhmad, H., Anjum, İ., Usman, H., Mobashar, A., Shabbir, A., Jardan, Y. A. B., Metouekel, A., Dauelbait, M., & Bourhia, M. (2025) · Open Life Sciences · doi:10.1515/biol-2025-1083 · Cited by 2
Lee, J., Kumar, N., Kabeto, M., Gałecki, A. T., Chang, C., Singh, N., Yung, R. L., Makris, U. E., & Bynum, J. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01125-w · Cited by 1
“In our cohort, long-term GC use was common and observed in one-third despite their well-known dose-and duration-dependent negative effects [49, 50].”
Atsumi, K., Nishima, S., Tanaka, T., Kamio, K., Taniuchi, N., Saito, Y., Shimizu, M., Okano, T., Seike, M., & Hirose, T. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002697 · Cited by 2
Tamaki, H. (2025) · Allergology International · doi:10.1016/j.alit.2025.10.004 · Cited by 3
You, S., Minn, D. K., Cha, Y.-J., Park, S.-B., Song, M., & Jung, S.-Y. (2026) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2026.152969 · Cited by 1
George, M. D., Gavigan, K., Venkatachalam, S., Curtis, D., Stradford, L., Nowell, W. B., Baker, J. F., Xie, F., & Curtis, J. R. (2026) · ACR Open Rheumatology · doi:10.1002/acr2.90050 · Cited by 1
“16,17,27 Additionally, nonserious infections frequently led to health care utilization, antibiotic use, or missed work, and approximately 20% of patients temporarily stopped RA medications because of their infection in our study.”
Self-citationExploring glucocorticoid dose–response patterns in VEXAS syndrome: a pilot retrospective study
Giachetti, N., Hadjadj, J., Gaudre, N., Lavigne, C., & Lacombe, V. (2026) · Rheumatology International · doi:10.1007/s00296-026-06130-3 · Cited by 1
Chen, J., Chen, P.-A., Peng, S., Lee, S., Chang, C.-H., Hu, C.-C., & Lin, Y.-C. (2026) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2026.153017 · Cited by 1
Wheeler, A. M., Baker, J. F., Barton, J. L., Danila, M. I., Johnson, T. M., Kuchinad, K., Michaud, K. D., Razmjou, A. A., Richards, J. S., Singh, N., et al. (2026) · Arthritis Care & Research · doi:10.1002/acr.80145 · Cited by 1
Self-citationCohen, L., Tiwari, V., Tesser, J., & Bergman, M. J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2718746 · Cited by 1
Ohmura, S., Ishihara, R., Mitsui, A., Otsuki, Y., & Miyamoto, T. (2021) · Case Reports in Rheumatology · doi:10.1155/2021/7842049 · Cited by 1
“Our patient received 8mg/day of methylprednisolone in combination with MTX and TCZ, which is consistent with previous studies [4, 19].”
BackgroundResultDubin, I., & Schattner, A. (2022) · QJM · doi:10.1093/qjmed/hcac197 · Cited by 1
Ogata-Medel, M., Llorente, L., Hinojosa‐Azaola, A., Lozada-Mellado, M., Pineda-Juárez, J. A., Rocha-González, H. I., & Castillo‐Martínez, L. (2022) · Clinical Rheumatology · doi:10.1007/s10067-022-06431-5 · Cited by 1
Outpatient glucocorticoid use and COVID-19 outcomes: a population-based study
Rodríguez-Fernández, A., Visos‐Varela, I., Zapata‐Cachafeiro, M., Pintos‐Rodríguez, S., García-Álvarez, R. M., Herdeiro, M. T., Piñeiro‐Lamas, M., Figueiras, A., Salgado‐Barreira, Á., COVIDRUG Group, et al. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01474-3 · Cited by 1
“This important risk of mortality could be accounted for: (i) By the increased risk of developing serious (George et al. 2020) or invasive fungal infections (Lionakis and Kontoyiannis 2003); (ii) By the harmful effect of glucocorticoid treat-ment in the initial stages of the disease (Li et al.…”
BackgroundYamashita, R., Kayama, Y., Izumi, Y., & Hiramoto, J. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6118-25 · Cited by 1
“However, it should be noted that long-term glucocorticoid use has been reported to increase the risk of severe infections, osteoporosis, and cardiovascular events with concurrent and continued use of glucocorticoids (9, 10, 23).”
Li, J., Zou, D., Luo, X., Hu, H., Zheng, P., Zhao, J., & Mo, L. (2023) · Research Square · doi:10.21203/rs.3.rs-3308919/v1 · Cited by 1
Bridging Gaps Amidst Limited Evidence for Glucocorticoid-Induced Adrenal Insufficiency
Lee, S. H. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2065 · Cited by 1
“Despite their efficacy, even low-dose GCs can increase risks of cardiovascular disease [5], severe infections [6], hypertension [7], diabetes [8], osteoporosis and fractures [9,10], and overall mortality [11].”
BackgroundAllen, V. B., & Galloway, J. B. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.03.020 · Cited by 1
Tschirschwitz, B., & Keyßer, G. (2021) · Aktuelle Rheumatologie · doi:10.1055/a-1371-1338
“[22] George MD, Baker JF, Winthrop K et al.”
BackgroundGlukokortikoide erhöhen Infektrisiko
(2020) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1246-8645
Hartman, L. M., da Silva, J. A. P., Buttgereit, F., Cutolo, M., Opriș-Belinski, D., Szekanecz, Z., Masaryk, P., Voshaar, M., Heymans, M. W., Lems, W. F., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac547
“In previous studies [27, 29, 30], Rheumatoid Arthritis Observation of Biologic Therapy risk score [26] and serious infections (with variable definitions) were strongly associated with increasing age, comorbidities, higher GC dosages and prior serious infections.”
Doumen, M., Pazmiño, S., Bertrand, D., Westhovens, R., & Verschueren, P. (2023) · Revue du Rhumatisme · doi:10.1016/j.rhum.2023.06.005
Dosis y tiempo de empleo de glucocorticoides en artritis reumatoide
Abud‐Mendoza, C., & vanOostdam, D. A. H. (2023) · Reumatología Clínica · doi:10.1016/j.reuma.2023.08.003
Menjo, H., Hasegawa, M., Fujigaki, H., Ishihara, T., Minatoguchi, S., Koide, S., Hayashi, H., Saito, M., Takahashi, K., Ito, H., et al. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1949-23
“An increased risk of infection with (cid:2) 5 mg prednisolone has also been re-ported (20).”
BackgroundHow Are Adjuvant Medications Such as Corticosteroids and NSAIDs Used for Pain Management?
Chilsen, A., Morphew, J., & Kamal, A. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-84702-5.00007-5
Dosage and time of use of glucocorticoids in rheumatoid arthritis
Abud‐Mendoza, C., & vanOostdam, D. A. H. (2023) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2023.08.001
Chen, C.-I., Jalbert, J. J., Wu, N., & Ruiz, E. S. (2023) · Future Oncology · doi:10.2217/fon-2023-0389
Antigen-Specific Immune Tolerance through Dendritic Cell Modulation
ter Braake, D. (2024) · Utrecht University Repository (Utrecht University) · doi:10.33540/2255
Turowski, T., Fleck, M., Ehrenstein, B. P., HARTUNG, W. M., & Günther, F. (2025) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/a-2479-8829
“U nau t ho r i z ed d i s t r i bu t i on i s s t r i c t l y p r oh i b i t ed . but are associated with serious adverse effects, especially when used for long-term treatment or at higher doses [9, 10, 11].”
Characterization of Ten Novel Metabolites of a PAF Antagonist SY0916 in Rats Using LC-MS and NMR
He, X., Zhang, T., Zhao, H.-Y., & Ma, C. (2025) · Metabolites · doi:10.3390/metabo15040238
“Anti-inflammatory drugs have various adverse effects, such as gastric mucosal damage and immunosuppression [4,5], which calls for more rational treatment options to alleviate the pain in affected individuals.”
Баранова, М. М., Muravyevа, N. V., & Belov, B. S. (2025) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2025-2-107-112
Evolution of Treatment for Autoimmune Pancreatitis: Recent Advancements
Katz, G., Bonaso, F., Perugino, C. A., & Hernandez-Barco, Y. G. (2025) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-025-00476-6
“Chronic low-dose glucocorticoids can also reduce relapse rates, but this practice is best avoided whenever possible due to the known risks of glucocorticoid toxicity with even doses as low as 5 mg prednisone equivalent taken over prolonged periods of time [43, 45, 46, 57].”
Urine Gram Stain in the Early Detection of an Enterovesical Fistula
Kuroda, M., Kuroda, K., & Kita, K. (2025) · Cureus · doi:10.7759/cureus.88038
“Older adults, particularly those with chronic conditions such as RA or those receiving long-term corticosteroids, may present with vague or atypical symptoms even when serious infections are present [16,17].”
Huang, Y., & Lu, M.-Y. (2025) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2025.09.052
Patel, N. J., Wang, J., Jiang, B., Jha, I., McMahon, G. A., McMahon, A. E., Chiha, T., Choi, H. K., & Stone, J. H. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152897
de Almeida, A. L. B., Guimarães, M. F. B. R., da Costa Pinto, M. R., Pereira, L. R., Reis, A. P. M. G., Bonfiglioli, K. R., Louzada-Junior, P., Giorgi, R. D. N., de Castro, G. R. W., Radominski, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26699609
Wang, Q., Gao, Q., Wang, Q.-C., Wu, L., Yu, Q., & He, P. (2023) · Figshare · doi:10.6084/m9.figshare.24013098
Abe, K., Ishikawa, Y., Kita, Y., Yajima, N., Inoue, E., Sada, K., Miyawaki, Y., Yoshimi, R., Shimojima, Y., Ohno, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20401351
de Almeida, A. L. B., Guimarães, M. F. B. D. R., da Costa Pinto, M. R., Pereira, L. R., Reis, A. P. M. G., Bonfiglioli, K. R., Louzada-Junior, P., Giorgi, R. D. N., de Castro, G. R. W., Radominski, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26699612
Sakellariou, G., Scirè, C. A., Rumi, F., Carrara, G., Zanetti, A., Cerra, C., Migliazza, S., Bugatti, S., & Montecucco, C. (2022) · Figshare · doi:10.6084/m9.figshare.20086048
Zhao, J. (2023) · University of Minnesota Digital Conservancy (University of Minnesota)
Enterococcal pyomyositis in a rheumatoid arthritis patient under biologic therapy
Gökten, D. B., & MERCAN, R. (2026) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-026-01784-7
Man, S., Ji, X., Ding, Y.-Y., Li, H.-C., Guo, S.-Y., Bian, T., & Zhang, L. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s576376
“8 This is based on the theoretical increased risk of perioperative complications, particularly surgical site infection and impaired wound healing.”
Vrachnis, D. N., & Stratakis, C. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-96100-4.00005-3
Carnota-Méndez, P., Remolí-Sargues, L., Copete, S., Fernández‐Vega, Á., Montero-Hernández, J., Zarranz‐Ventura, J., Alforja, S., Renú, A., Cubero, A. D.-M., Gómez‐Ulla, F., et al. (2026) · Ophthalmologica · doi:10.1159/000551309
Vaduva, P., Bonnet, F., Fauchier, G., Raverot, G., Bertherat, J. Y., & Fauchier, L. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag051
Yamane, T., Inoue, A., Yasuda, N., Ohnishi, T., & Hashiramoto, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1797242
“Although even low-dose GC use has been associated with increased risks of infection, osteoporosis, and cardiovascular events (2–4), and recent treatment guidelines for autoimmune diseases, including systemic lupus erythematosus and connective tissue disease–associated interstitial lung disease…”
Lee, J., Pedro, S., Bares, S. H., Ozen, G., Mikuls, T. R., & Michaud, K. D. (2026) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x261433254
“25 In addition to dose, the timing and duration of GC use substantially increased SI risk.”
Défaut de tolérance des lymphocytes B et sa restauration dans les maladies auto-immunes
Mirouse, A. (2024) · theses.fr (ABES) · doi:10.70675/3fe102f3ze597z473azb130zf7788274f05a
Wu, C. J., & Chang, R. (2026) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70677
Zhang, Q., Qi, Y., Wang, X., McDermott, G. C., Chang, S. H., Chaballa, M., Khaychuk, V., Paudel, M. L., Liao, K. P., & Sparks, J. A. (2026) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2026.152996
Glucocorticoid use and candidemia: results from a nationwide case-control study
Leding, C., Meddis, A., Holler, J. G., Astvad, K. M. T., & Benfield, T. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.05.033
Décroissance de la corticothérapie dans la polyarthrite rhumatoïde
Forien, M. (2026) · Revue du Rhumatisme · doi:10.1016/j.rhum.2026.06.022
Dağ, H. H., van Onna, M., Dolhain, R. J. E. M., & de Jong, P. H. P. (2026) · RMD Open · doi:10.1136/rmdopen-2026-007055
Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?
Spagnolo, P., & Miedema, J. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001293
Beydon, M., Lacaille, D. V., Fautrel, B., Séror, R., Hajage, D., & Tubach, F. (2026) · RMD Open · doi:10.1136/rmdopen-2026-006866
George, M., Reed, G., Kearney, M. D., Cronholm, P. F., Kane, K., Curtis, J. R., Pappas, D. A., & Kremer, J. M. (2026) · Arthritis Care & Research · doi:10.1002/acr.80119
Self-citationXin, T., Wang, C., Gong, F., Zhao, Y., He, J. C., Wang, X., Nie, D., Jin, G., & Liu, A. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1884282
“Glucocorticoids and DMARDs can affect immune function, infection susceptibility, and systemic inflammatory responses, thereby potentially influencing both NAR levels and SAE risk (3, 24, 25).”
The longer the better? Duration of corticosteroid treatment for mild immune-related pneumonitis
Spagnolo, P. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag407
Peng, K., Yang, D., Wang, J., Shen, C., Cheng, M. C., Chan, S. C. W., Tang, I. Y. K., Zhang, Q., Lai, E. C., Pratt, N. L., et al. (2026) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-026-03739-z
“Other factors associated with serious infection include age, comorbidities (e.g., cancer), inflammation status [e.g., C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)], medication use (e.g., opioid and glucocorticoids) [15, 16].”
Khairallah, E., Sporn, K., & Khairallah, R. (2026) · Springer eBooks · doi:10.1007/978-3-032-26761-0_28
Jereisat, R. A., Ammari, S., & Ibrahim, N. (2026) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2026_007257
Wang, Y., Jin, L., Huan, X., Chen, R., He, D., Zhong, H., Zhao, R., Xi, J., Chong, Y., Song, J., et al. (2026) · BMC Neurology · doi:10.1186/s12883-026-05271-z
Khired, Z., Abdelrazek, M., Aljonaid, M., Ramadan, H., Soliman, A. M., Elshewy, N. A. L. F., Abdou, M. H. Y., Alharthi, H. T., Gazar, Y., Ali, M., et al. (2026) · La Clinica Terapeutica · doi:10.7417/ct.2026.2127
Zhang, K., Tan, X., Wei, C., Yang, H., Zhang, C., Wei, L., Li, K., & Xie, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10704717/v1
Hanbashi, A. (2026) · Authorea · doi:10.22541/authorea.15008712/v1
Sudireddy, D., Leung, B., Neogi, T., LaValley, M. P., Felson, D. T., Flynn, D., & Liew, J. W. (2026) · Joint Bone Spine · doi:10.1016/j.jbspin.2026.106142
Metadata
- Authors
- George, M. D., Baker, J. F., Winthrop, K., Hsu, J. Y., Wu, Q., Chen, L., Xie, F., Yun, H., & Curtis, J. R.
- Affiliations
- University of Pennsylvania (US)
- Philadelphia VA Medical Center (US)
- Oregon Health & Science University (US)
- University of Alabama at Birmingham (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-12-01
- Volume
- 173
- Issue
- 11
- Pages
- 870-878
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC8073808
- OpenAlex
- W3087498606
- Cited by
- 198
- References
- 30
- Citations by year
- 2026: 35 · 2025: 33 · 2024: 32 · 2023: 38 · 2022: 38 · 2021: 19 · 2020: 3
- FWCI
- 18.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (1K23AR073931-01)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- rheumatoid arthritis, low-dose glucocorticoids, hospitalized infection, infection risk, disease-modifying antirheumatic drugs, glucocorticoid dose, long-term glucocorticoid use, adverse drug reactions, Medicare beneficiaries, cumulative incidence, inverse probability weighting, propensity score matching, immunosuppression
- MeSH terms
- Aged, Arthritis, Rheumatoid, Female, Glucocorticoids, Hospitalization, Humans, Infections, Male, Retrospective Studies, Risk Factors, Antirheumatic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.